Literature DB >> 24365286

Neurologic complications of cardiac arrest.

Matthew McCoyd1, Thomas McKiernan2.   

Abstract

Cardiac arrest is a common and serious medical emergency affecting upwards of 450000 Americans on an annual basis. It causes a substantial strain on the physical and financial resources of the medical system. The optimal management of patients requires the close collaboration of multiple specialists, including first responders, intensivists, cardiologists, and neurologists. The role of the neurologist for the post-arrest patient is to assist in management to minimize brain injury as well as to prognosticate long-term outcomes to help guide therapy decisions of families and physicians. This review focuses on epidemiologic data, current management recommendations, clinical and ancillary testing to suggest long-term prognosis, and common complications of cardiac arrest. Particular attention has been paid to updates, including therapeutic hypothermia, since this topic was last reviewed in 1993.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24365286     DOI: 10.1016/B978-0-7020-4086-3.00003-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  3 in total

1.  The effect of epinephrine and methylprednisolone on cardiac arrest patients.

Authors:  Hooman Rafiei; Nasrin Bahrami; Amir Hossein Meisami; Haniyeh Azadifar; Shahrouz Tabrizi
Journal:  Ann Med Surg (Lond)       Date:  2022-05-20

2.  Prognostic value of 18F-FDG brain PET as an early indicator of neurological outcomes in a rat model of post-cardiac arrest syndrome.

Authors:  Daehee Kim; Hai-Jeon Yoon; Woon Jeong Lee; Seon Hee Woo; Bom Sahn Kim
Journal:  Sci Rep       Date:  2019-10-15       Impact factor: 4.379

3.  CTL-Derived Granzyme B Participates in Hippocampal Neuronal Apoptosis Induced by Cardiac Arrest and Resuscitation in Rats.

Authors:  Ning-Ning Ji; Liang Wu; Bo-Ming Shao; Qing-Xiang Meng; Jin-Nan Xu; Hao-Wen Zhu; Yong-Mei Zhang
Journal:  Front Neurol       Date:  2019-12-12       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.